Global Protein Therapeutics Market Size Grows at a CAGR of 7.06%

Introduction

Straits Research released its highly anticipated report, “Protein Therapeutics Market Size & Outlook, 2026-2034.” According to the study, the global market size is valued at USD 399.76 billion in 2025 and is projected to expand to USD 736.06 billion by 2034, registering a compound annual growth rate (CAGR) of 7.06%.

Market Dynamics

The market growth is primarily attributed to the expansion of monoclonal antibody and recombinant protein applications, and increased investment in biopharmaceutical R&D. In addition, the increasing prevalence of chronic diseases, such as cancer worldwide, is driving the demand for innovative protein-based therapies, including monoclonal antibodies and targeted treatments. For example, in February 2024, as per the WHO, global cancer cases are projected to exceed 35 million annually by 2050, emphasizing the urgent need for effective therapies. This rising incidence of cancer fuels the demand for protein therapeutics, supporting the growth of the global protein therapeutics market. Moreover, technological advancements in protein therapeutics present significant opportunities for developing targeted and effective treatments for various cancers and chronic diseases. For example, in April 2025, Amgen’s UPLIZNA (inebilizumab-cdon) received FDA approval for Immunoglobulin G4-related disease (IgG4-RD), expanding its therapeutic applications beyond NMOSD and demonstrating the potential of next-generation antibody therapies. These advancements offer companies the opportunity to innovate and expand their protein therapeutics portfolio, addressing unmet medical needs and capturing new market segments.

Market Highlights

• Product: The Monoclonal Antibodies segment dominated the market in 2025 with a revenue share of 37.21%.
• Application: The Immunologic Disorders segment is estimated to grow at the fastest pace with a CAGR (8.93%) during the forecast period, fuelled by the rising prevalence of autoimmune and chronic inflammatory diseases, and increasing adoption of protein-based immunotherapies. 
• Regional Insights: North America dominated the market with a 46.92% share, driven by the rising prevalence of chronic and rare diseases. 

Competitive Players

1. Bayer AG
2. Bristol-Myers Squibb Company
3. DAIICHI SANKYO COMPANY, LIMITED
4. Abbott
5. Sanofi
6. Thermo Fisher Scientific, Inc.
7. Alligator Bioscience AB
8. AbbVie Inc. 
9. Takeda Pharmaceutical Company Limited.
10. Amgen Inc.
11. Hoffmann-La Roche Ltd 
12. Lilly USA
13. Pfizer Inc.
14. Novo Nordisk A/S 
15. Genmab A/S
16. BioMarin
17. CSL
18. Regeneron Pharmaceuticals Inc.
19. Vertex Pharmaceuticals Incorporated
20. Kyowa Kirin Co., Ltd.
21. Others

Recent Developments

Segmentation

1. By Product (2026-2034)
   1. Monoclonal Antibodies
   2. Insulin
   3. Fusion Protein
   4. Erythropoietin
   5. Interferon
   6. Human Growth Hormone
   7. Follicle Stimulating Hormone
2. By Applications (2026-2034)
   1. Metabolic Disorders
   2. Immunologic Disorders
   3. Haematological Disorders
   4. Cancer
   5. Genetic Disorders
   6. Others